...
首页> 外文期刊>Trials >Combined STN/SNr-DBS for the treatment of refractory gait disturbances in Parkinson's disease: study protocol for a randomized controlled trial
【24h】

Combined STN/SNr-DBS for the treatment of refractory gait disturbances in Parkinson's disease: study protocol for a randomized controlled trial

机译:联合STN / SNr-DBS治疗帕金森氏病的难治性步态障碍:一项随机对照试验的研究方案

获取原文
           

摘要

Background Severe gait disturbances in idiopathic Parkinson's disease (PD) are observed in up to 80% of all patients in advanced disease stages with important impact on quality of life. There is an unmet need for further symptomatic therapeutic strategies, particularly as gait disturbances generally respond unfavourably to dopaminergic medication and conventional deep brain stimulation of the subthalamic nucleus in advanced disease stages. Recent pathophysiological research pointed to nigro-pontine networks entrained to locomotor integration. Stimulation of the pedunculopontine nucleus is currently under investigation, however, hitherto remains controversial. The substantia nigra pars reticulata (SNr) - entrained into integrative locomotor networks - is pathologically overactive in PD. High-frequent stimulation of the substantia nigra pars reticulata preferentially modulated axial symptoms and therefore is suggested as a novel therapeutic candidate target for neuromodulation of refractory gait disturbances in PD. Methods 12 patients with idiopathic Parkinson's disease and refractory gait disturbances under best individual subthalamic nucleus stimulation and dopaminergic medication will be enroled into this double-blind 2 × 2 cross-over clinical trial. The treatment consists of two different stimulation settings using (i) conventional stimulation of the subthalamic nucleus [STNmono] and (ii) combined stimulation of distant electrode contacts located in the subthalamic nucleus and caudal border zone of STN and substantia nigra pars reticulata [STN+SNr]. The primary outcome measure is the change of the cumulative 'axial score' (UPDRS II items '13-15' and UPRDS III items '27-31') at three weeks of constant stimulation in either condition. Secondary outcome measures include specific scores on freezing of gait, balance function, quality of life, non-motor symptoms, and neuropsychiatric symptoms. The aim of the present trial is to investigate the efficacy and safety of a three week constant combined stimulation on [STN+SNr] compared to [STNmono]. The results will clarify, whether stimulation on nigral contacts additional to subthalamic stimulation will improve therapeutic response of otherwise refractory gait disturbances in PD. Trial registration The trial was registered with the clinical trials register of http://www.clinicaltrials.gov webcite ( NCT01355835 )
机译:背景技术特发性帕金森病(PD)的严重步态障碍在所有处于疾病晚期的患者中,高达80%都被观察到,这对生活质量产生了重要影响。尚无进一步的对症治疗策略的需求,特别是由于步态障碍通常对多巴胺能药物和晚期疾病阶段丘脑底核的常规深层脑刺激产生不利反应。最近的病理生理研究指出,黑质桥神经网络具有运动整合能力。目前正在研究对小足鸟足核的刺激,但是至今仍存在争议。黑质网状组织(SNr)-夹带到完整的运动网络中-在PD中病理上过度活跃。黑质网状的高频刺激优先调节轴向症状,因此被建议作为PD难治性步态障碍的神经调节的新型治疗候选靶点。方法将12名特发性帕金森病和难治性步态障碍患者在最佳的单独丘脑底核刺激和多巴胺能药物刺激下纳入该双盲2×2交叉临床试验。该治疗包括两种不同的刺激设置,分别是(i)丘脑底核[STNmono]的常规刺激和(ii)丘脑底核和STN和黑质网状尾部[STN + SNr]。主要结局指标是在任何一种情况下,持续刺激三周后,累积“轴向评分”(UPDRS II项目“ 13-15”和UPRDS III项目“ 27-31”)的变化。次要结局指标包括步态冻结,平衡功能,生活质量,非运动症状和神经精神症状的特定评分。本试验的目的是研究与[STNmono]相比,三周持续联合刺激对[STN + SNr]的疗效和安全性。结果将阐明,除丘脑下刺激外,对黑质接触的刺激是否会改善PD难治性步态障碍的治疗反应。试验注册该试验已在http://www.clinicaltrials.gov网站(NCT01355835)的临床试验注册簿中注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号